CA2744340A1 - Procede de determination d'activite de facteur de coagulation sanguine pegyle dans un essai de temps de thromboplastine partielle activee a base de silice - Google Patents

Procede de determination d'activite de facteur de coagulation sanguine pegyle dans un essai de temps de thromboplastine partielle activee a base de silice Download PDF

Info

Publication number
CA2744340A1
CA2744340A1 CA2744340A CA2744340A CA2744340A1 CA 2744340 A1 CA2744340 A1 CA 2744340A1 CA 2744340 A CA2744340 A CA 2744340A CA 2744340 A CA2744340 A CA 2744340A CA 2744340 A1 CA2744340 A1 CA 2744340A1
Authority
CA
Canada
Prior art keywords
peg
blood coagulation
conjugated
coagulation factor
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2744340A
Other languages
English (en)
Inventor
Liang Tang
Heiner Apeler
Philip Ramsey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CA2744340A1 publication Critical patent/CA2744340A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
CA2744340A 2008-11-24 2009-11-24 Procede de determination d'activite de facteur de coagulation sanguine pegyle dans un essai de temps de thromboplastine partielle activee a base de silice Abandoned CA2744340A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11734508P 2008-11-24 2008-11-24
US61/117,345 2008-11-24
PCT/US2009/065732 WO2010060081A1 (fr) 2008-11-24 2009-11-24 Procédé de détermination d’activité de facteur de coagulation sanguine pégylé dans un essai de temps de thromboplastine partielle activée à base de silice

Publications (1)

Publication Number Publication Date
CA2744340A1 true CA2744340A1 (fr) 2010-05-27

Family

ID=42198546

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2744340A Abandoned CA2744340A1 (fr) 2008-11-24 2009-11-24 Procede de determination d'activite de facteur de coagulation sanguine pegyle dans un essai de temps de thromboplastine partielle activee a base de silice

Country Status (4)

Country Link
EP (1) EP2368124A4 (fr)
JP (1) JP2012510060A (fr)
CA (1) CA2744340A1 (fr)
WO (1) WO2010060081A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772051C (fr) 2009-08-24 2020-08-18 Amunix Operating Inc. Compositions de facteur ix de coagulation et leurs procedes de fabrication et d'utilisation
WO2013076157A1 (fr) * 2011-11-22 2013-05-30 Universite Catholique De Louvain Marqueur pour la coagulation sanguine
SI2804623T1 (sl) 2012-01-12 2020-02-28 Bioverativ Therapeutics Inc. Himerni polipeptidi faktorja VIII in njihove uporabe
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
ES2935489T3 (es) 2012-02-15 2023-03-07 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
PT2882450T (pt) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
US20160229903A1 (en) * 2013-06-28 2016-08-11 Biogen Ma Inc. Thrombin cleavable linker
EP3013358A4 (fr) * 2013-06-28 2017-03-22 Biogen MA Inc. Lieur pouvant être fendu par thrombine ayant un xten et ses utilisations
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
IL246476B (en) 2014-01-10 2022-06-01 Biogen Ma Inc Factor viii chimeric proteins and their uses
CN107110875A (zh) 2014-09-26 2017-08-29 雅培医护站股份有限公司 用在凝固测定中的鞣花酸制剂
EP3198270A1 (fr) 2014-09-26 2017-08-02 Abbott Point Of Care, Inc. Dispositif cartouche avec jonctions fluidiques pour mesures de coagulation dans des échantillons de fluide
US10114031B2 (en) 2014-09-26 2018-10-30 Abbott Point Of Care Inc. Single channel cartridge device for coagulation assays in fluid samples
WO2016049515A1 (fr) 2014-09-26 2016-03-31 Abbott Point Of Care Inc. Dispositif microfabriqué avec des capteurs de microenvironnement pour analyser la coagulation dans des échantillons fluides
EP3197603A1 (fr) 2014-09-26 2017-08-02 Abbott Point of Care Inc. Dispositif de cartouche avec système fluidique segmenté pour effectuer des essais de coagulation dans des échantillons liquides
ES2881861T3 (es) 2014-09-26 2021-11-30 Abbott Point Of Care Inc Sensores para evaluar la coagulación en muestras de fluidos
US10473612B2 (en) 2014-09-26 2019-11-12 Abbott Point Of Care Inc. Cartridge device identification for coagulation assays in fluid samples
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
CN108344875B (zh) * 2017-01-22 2021-11-02 上海长岛生物技术有限公司 提高活化部分凝血活酶时间试剂对肝素敏感性的方法及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005106042A2 (fr) * 2004-04-22 2005-11-10 Regado Biosciences, Inc. Modulateurs ameliores des facteurs de coagulation
US20080026476A1 (en) * 2004-05-20 2008-01-31 Steven Howell Device and Method for Detecting Blood Coagulation
RU2423380C2 (ru) * 2004-11-12 2011-07-10 БАЙЕР ХЕЛСКЕА ЛЛСи Сайт-направленная модификация fviii
CN101226201B (zh) * 2008-02-05 2011-05-11 长安大学 活化部分凝血活酶时间(aptt)测定试剂

Also Published As

Publication number Publication date
EP2368124A1 (fr) 2011-09-28
WO2010060081A1 (fr) 2010-05-27
JP2012510060A (ja) 2012-04-26
EP2368124A4 (fr) 2012-09-19

Similar Documents

Publication Publication Date Title
CA2744340A1 (fr) Procede de determination d'activite de facteur de coagulation sanguine pegyle dans un essai de temps de thromboplastine partielle activee a base de silice
US7884075B2 (en) Polymer-factor VIII-von Willebrand factor-conjugates
DK2349342T3 (en) MODIFIED BLOOD FACTORS INCLUDING A LOW DEGREE OF WATER SOLUBLE POLYMER
WO2002003075A2 (fr) Procedes de detection de l'activite de facteurs de coagulation
MX2008012600A (es) Factor viii pegilado.
JP2008530208A (ja) 万能前凝固薬
US20170227557A1 (en) Method and compositions for specifically detecting physiologically acceptable polymer molecules
Lefkowitz et al. Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot‐based test results only when using an optical detection method
CA2905739A1 (fr) Formulations de facteur viii recombinant
WO2010088547A1 (fr) Dosages de détection de facteurs de coagulation sanguine pégylés
AU2014265111B2 (en) Method And Compositions For Specifically Detecting Physiologically Acceptable Polymer Molecules
Aly et al. Cysteamine enhances the procoagulant activity of factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine).
JPH0820440B2 (ja) 血液凝固促進剤

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20131126